1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Combinations Key For Amgen’s Lumakras, But PD-1/L1 Data Held Until August

Combo Importance Increases With Sales Growth Slowing

 
• By Mandy Jackson

A World Conference on Lung Cancer abstract shows responses to Lumakras with a SHP2 inhibitor but closely watched results for anti-PD-1/L1 combinations are under embargo until the meeting next month.

Lungs icon, anatomy, health care concept
Amgen's first Lumakras combination therapy results in lung cancer will be presented at WCLC • Source: Shutterstock

One of two highly anticipated datasets for Amgen, Inc.’s KRAS G12C inhibitor Lumakras (sotorasib) in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC) was released late on 12 July when the World Conference on Lung Cancer (WCLC) published abstracts for next month’s meeting. The initial efficacy findings for use with Revolution Medicines, Inc.’s SHP2 inhibitor are inconclusive due to small NSCLC patient numbers, but the safety results appear reasonable ahead of anti-PD-1/L1 combination results being unveiled at the conference in August.

Amgen was the first company to bring a KRAS G12C inhibitor to the market and has maintained its lead even with Mirati Therapeutics, Inc.’s adagrasib following closely behind; adagrasib...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod

 
• By Kevin Grogan

The UK major's asthma drug gets a key expanded approval.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

More from R&D

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.